Sofinnova Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$44.2M Buy
781,982
+84,849
+12% +$4.95M 1.68% 18
2025
Q4
$41.4M Buy
+697,133
New +$38M 1.79% 16
2023
Q2
Sell
-359,035
Closed -$34.9M 56
2023
Q1
$34.9M Sell
359,035
-35,608
-9% -$3.69M 2.23% 12
2022
Q4
$40.8M Buy
394,643
+99,893
+34% +$9.38M 2.42% 12
2022
Q3
$25M Sell
294,750
-6,855
-2% -$610K 1.45% 17
2022
Q2
$25M Buy
301,605
+125,072
+71% +$9.96M 2.08% 13
2022
Q1
$13.6M Buy
176,533
+89,211
+102% +$7.46M 1.03% 24
2021
Q4
$7.71M Buy
+87,322
New +$7.21M 0.45% 48
2021
Q1
Sell
-164,545
Closed -$14.4M 69
2020
Q4
$14.4M Sell
164,545
-94,108
-36% -$7.46M 0.86% 26
2020
Q3
$19.7M Buy
258,653
+195,756
+311% +$19.8M 1.46% 17
2020
Q2
$7.76M Sell
62,897
-177,149
-74% -$17.6M 0.49% 41
2020
Q1
$20.3M Sell
240,046
-201,826
-46% -$17.4M 1.88% 15
2019
Q4
$37.4M Buy
441,872
+356,976
+420% +$27M 2.69% 9
2019
Q3
$5.72M Hold
84,896
0.52% 42
2019
Q2
$7.27M Buy
84,896
+66,402
+359% +$5.68M 0.67% 35
2019
Q1
$1.64M Sell
18,494
-122,048
-87% -$11.3M 0.16% 59
2018
Q4
$12M Buy
+140,542
New +$13.4M 1.49% 19

Other funds holding BMRN

Sofinnova Investments's BMRN Position: Q1 2026 in Review

Sofinnova Investments increased its BioMarin Pharmaceuticals (BMRN) stake by 12% in Q1 2026, buying an estimated $4.95M and bringing the position to 781,982 shares worth $44.2M. The position accounts for 1.68% of the portfolio, ranked #18.

Sofinnova Investments first reported a position in BMRN in Q4 2018 and has held it in 17 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Sofinnova Investments held 781,982 shares of BioMarin Pharmaceuticals worth $44.2M as of Q1 2026.
  • Sofinnova Investments bought 84,849 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $4.95M.
  • BioMarin Pharmaceuticals made up 1.68% of Sofinnova Investments's portfolio in Q1 2026, its #18 holding.
  • Sofinnova Investments first reported a position in BioMarin Pharmaceuticals in Q4 2018 and has held it in 17 quarters since.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.